Mqs Management LLC Incyte Corp Transaction History

Mqs Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$56.55 - $66.59 $319,224 - $375,900	5,645 New	5,645 $321,000
Q3 2023 Nov 13, 2023	BUY	$57.77 - $65.93 $18,890 - $21,559	327 Added 6.22%	5,581 $322,000
Q2 2023 Aug 10, 2023	SELL	$60.95 - $75.51 $354,911 - $439,694	-5,823 Reduced 52.57%	5,254 $327,000
Q1 2023 May 05, 2023	BUY	$70.23 - $86.01 $777,937 - $952,732	11,077 New	11,077 $800,000
Q3 2022 Nov 09, 2022	BUY	$66.18 - $82.86 $230,835 - $289,015	3,488 Added 88.24%	7,441 $496,000
Q2 2022 Aug 05, 2022	BUY	$66.18 - $83.18 $261,609 - $328,810	3,953 New	3,953 $300,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.6B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Mqs Management LLC, based on Form 13F filings with the SEC.

Stay updated on Mqs Management LLC with notifications on news.